Shuttle Pharmaceuticals Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.1M
- Price
- $3.25
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.96%
- Volume
- 2.4M
Quote data as of 5:17 AM ET
About
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Quick stats
Shares outstanding585.1K
Computed float382.4K
Float sourceUnknown
Cash runway (months)-1.6
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001757499